Bifidobacterium longum was isolated from microbial inoculum. It is a Gram-positive, catalase-negative, rod-shaped bacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT
Size
Price
Quantity
LBGF-0722-GF12
Product Information
Product Overview
Bifidobacterium longum was isolated from microbial inoculum. It is a Gram-positive, catalase-negative, rod-shaped bacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants.
Target
Bifidobacterium
Genus
Bifidobacterium
Strain Designation
S12
Application
Study and research
Type Strain
Yes
Culture Medium
BBL
Culture Conditions
37°C; Anaerobic
Source
Infant gut
Risk Group
1
Product Format
Freeze-dried
Packaging
Ampoule tube
Storage
-80°C
Shelf Life
6 years
Target Introduction
Introduction
Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.
Alternative Names
Bifidobacterium longum; 1222
FAQsPublished Data Customer Reviews Related Products
What types of culture media are suitable for growing Bifidobacterium longum ?
Bifidobacterium longum can be grown in various culture media, including MRS broth supplemented with cysteine, Reinforced Clostridial Medium (RCM), or any other anaerobic medium that supports the growth of Bifidobacteria.
What methods are used to quantify Bifidobacterium longum in research samples?
Quantification of Bifidobacterium longum can be performed using colony-forming unit (CFU) counts on selective agar plates, quantitative PCR (qPCR) targeting specific genetic markers, or flow cytometry to analyze bacterial cell populations in complex samples.
What is the optimal inoculum size for Bifidobacterium longum in cell culture studies?
The optimal inoculum size for Bifidobacterium longum in cell culture studies typically ranges from 10^6 to 10^8 CFU/mL, depending on the experimental design and desired outcomes. Adjustments may be necessary based on preliminary experiments.
What controls are recommended for experiments involving Bifidobacterium longum ?
Experiments involving Bifidobacterium longum should include both positive and negative controls. Positive controls could be a well-characterized probiotic strain known for its efficacy, while negative controls should include a sterile medium without any bacterial inoculation.
Oral treatment of B. longum 1222 (B.l) alleviates DSS-induced acute colitis
The study investigated the anti-inflammatory effects of Bifidobacterium longum 1222 on dextran sulfate sodium (DSS)-induced colitis in mice. Oral administration of B. longum 1222 significantly alleviated symptoms of acute colitis, as evidenced by reduced body weight loss, lower Disease Activity Index (DAI) scores, and maintenance of colon length. Histological analysis showed less tissue damage and lower infiltration of inflammatory cells in the treated group compared to the DSS-only group. Additionally, B. longum 1222 treatment suppressed the production of pro-inflammatory cytokines such as IL-17A and IFN-γ, as well as the expression of Th17-specific transcription factors in colonic tissue. The treatment also decreased the expression of costimulatory molecules CD80 and CD40 on intestinal epithelial cells (IECs), which are involved in T cell activation and differentiation. These findings highlight the potential of B. longum 1222 as a therapeutic agent for IBD, demonstrating its ability to modulate immune responses and reduce intestinal inflammation. The suppression of IL-17A production and downregulation of costimulatory molecules on IECs suggest a novel mechanism through which B. longum 1222 exerts its anti-inflammatory effects.
Miyauchi, E., Ogita, T., et al. Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PloS one. 2013, 8(11): e79735. Distributed under Open Access license CC BY 4.0, without modification.
Exceptional Viability and Stability Bifidobacterium longum 1222 from Creative Biolabs demonstrates exceptional viability and stability in anaerobic culture conditions, surpassing similar products in research applications.
Superior Quality for Immunomodulation Research
The superior quality of Creative Biolabs' Bifidobacterium longum 1222 enhances research into immunomodulation, providing consistent and reproducible results. It stands out compared to other suppliers' products.
Enhanced Consistency in Experimental Outcomes
Utilizing Bifidobacterium longum 1222 from Creative Biolabs ensures enhanced consistency in experimental outcomes, making it an invaluable tool in probiotic efficacy studies.
Outstanding Results in Probiotic Mechanism Studies Bifidobacterium longum 1222 provides outstanding results in probiotic mechanism studies, offering superior growth and activity.
Click the button below to contact us or submit your feedback about this product.
